Literature DB >> 34387242

Modulation of Xenogeneic T-cell Proliferation by B7 and mTOR Blockade of T Cells and Porcine Endothelial Cells.

Shu Li1, He Xu, Allan D Kirk.   

Abstract

BACKGROUND: Activation of porcine endothelial cells (PECs) is the mechanistic centerpiece of xenograft rejection. This study sought to characterize the immuno-phenotype of human T cells in response to PECs and to explore the immuno-modulation of B7 and mammalian target of rapamycin blockade of T cells and/or PECs during xeno-responses.
METHODS: Rapid memory T-cell (TM) responses to PECs were assessed by an intracellular cytokine staining. T-cell proliferation to PEC with or without belatacept or rapamycin was evaluated by a mixed lymphocyte-endothelial cell reaction (MLER). Additionally, rapamycin-pretreated PECs were used in MLER. Cell phenotypes were analyzed by flow cytometry.
RESULTS: Tumor necrosis factor-α/interferon-γ producers were detected in CD8+ cells stimulated by human endothelium but not PECs. MLER showed proliferation of CD4+ and CD8+ cells with predominantly memory subsets. Purified memory and naive cells proliferated following PEC stimulation with an increased frequency of TM in PEC-stimulated naive cells. Proliferating cells upregulated programmed cell death-1 (PD-1) and CD2 expression. Belatacept partially inhibited T-cell proliferation with reduced CD2 expression and frequency of the CD8+CD2highCD28- subset. Rapamycin dramatically inhibited PEC-induced T-cell proliferation, and rapamycin-preconditioned PECs failed to induce T-cell proliferation. PD-1 blockade did not restore T-cell proliferation to rapamycin-preconditioned PECs.
CONCLUSIONS: Humans lack rapid TM-mediated responses to PECs but induce T-cell proliferative responses characterized largely as TM with increasing CD2 and PD-1 expression. B7-CD28 and mammalian target of rapamycin blockade of T cells exhibit dramatic inhibitory effects in altering xeno-proliferating cells. Rapamycin alters PEC xeno-immunogenicity leading to inhibition of xeno-specific T-cell proliferation independent of PD-1-PD ligand interaction.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34387242      PMCID: PMC8850983          DOI: 10.1097/TP.0000000000003920

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   5.385


  59 in total

1.  Maintenance triple immunosuppression with cyclosporin A, mycophenolate sodium and steroids allows prolonged survival of primate recipients of hDAF porcine renal xenografts.

Authors:  Emanuele Cozzi; Conrad Vial; Daniel Ostlie; Bhatti Farah; Gilda Chavez; Kenneth G C Smith; John R Bradley; Sathia Thiru; Hugh F S Davies; John Wallwork; David J G White; Martin Goddard; Peter J Friend
Journal:  Xenotransplantation       Date:  2003-07       Impact factor: 3.907

2.  T cell independence of macrophage and natural killer cell infiltration, cytokine production, and endothelial activation during delayed xenograft rejection.

Authors:  D Candinas; S Belliveau; N Koyamada; T Miyatake; P Hechenleitner; W Mark; F H Bach; W W Hancock
Journal:  Transplantation       Date:  1996-12-27       Impact factor: 4.939

3.  Human platelets activate porcine endothelial cells through a CD154-dependent pathway.

Authors:  H Xu; F Arnaud; D K Tadaki; L C Burkly; D M Harlan; A D Kirk
Journal:  Transplantation       Date:  2001-12-15       Impact factor: 4.939

4.  CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates.

Authors:  P Thompson; K Cardona; M Russell; I R Badell; V Shaffer; G Korbutt; G R Rayat; J Cano; M Song; W Jiang; E Strobert; R Rajotte; T Pearson; A D Kirk; C P Larsen
Journal:  Am J Transplant       Date:  2011-05       Impact factor: 8.086

5.  Human T lymphocyte proliferative response to resting porcine endothelial cells results from an HLA-restricted, IL-10-sensitive, indirect presentation pathway but also depends on endothelial-specific costimulatory factors.

Authors:  I Vallée; J M Guillaumin; G Thibault; Y Gruel; Y Lebranchu; P Bardos; H Watier
Journal:  J Immunol       Date:  1998-08-15       Impact factor: 5.422

6.  Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells.

Authors:  Chen Wang; Tai Yi; Lingfeng Qin; Roberto A Maldonado; Ulrich H von Andrian; Sanjay Kulkarni; George Tellides; Jordan S Pober
Journal:  J Clin Invest       Date:  2013-03-08       Impact factor: 14.808

7.  Heterologous immunity provides a potent barrier to transplantation tolerance.

Authors:  Andrew B Adams; Matthew A Williams; Thomas R Jones; Nozomu Shirasugi; Megan M Durham; Susan M Kaech; E John Wherry; Thandi Onami; J Gibson Lanier; Kenneth E Kokko; Thomas C Pearson; Rafi Ahmed; Christian P Larsen
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

8.  Evidence that activation of human T cells by porcine endothelium involves direct recognition of porcine SLA and costimulation by porcine ligands for LFA-1 and CD2.

Authors:  S A Rollins; S P Kennedy; A J Chodera; E A Elliott; G B Zavoico; L A Matis
Journal:  Transplantation       Date:  1994-06-27       Impact factor: 4.939

9.  The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation.

Authors:  H Xu; S D Perez; J Cheeseman; A K Mehta; A D Kirk
Journal:  Am J Transplant       Date:  2014-02       Impact factor: 8.086

10.  CD57(+) CD4 T Cells Underlie Belatacept-Resistant Allograft Rejection.

Authors:  J Espinosa; F Herr; G Tharp; S Bosinger; M Song; A B Farris; R George; J Cheeseman; L Stempora; R Townsend; A Durrbach; A D Kirk
Journal:  Am J Transplant       Date:  2016-01-14       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.